diabetestalk.net

Lantus Solostar Reusable Pen

Support For Lantus (insulin Glargine Injection) 100 Units/ml

Support For Lantus (insulin Glargine Injection) 100 Units/ml

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs, including any state pharmaceutical programs. The Federal Employee Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. For the duration of the program, the Savings Card carries maximum savings up to: $500 per pack for all patients who are enrolled in a commercial insurance plan, regardless of formulary status $100 per pack of Lantus for patients not enrolled in a commercial insurance plan This offer is valid for up to 3 packs per prescription. Savings may vary depending on patients out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice. 1Januvia is a registered trademark of Merck & Co., Inc. 2Onglyza and 10Bydureon are registered trademarks of the AstraZeneca group of companies. 3Actos is a registered trademark of Takeda Pharmaceutical Company, Ltd. 4Levemir, 5Tresiba, 6Novolog, and 8Victoza are registered trademarks of Novo Nordisk A/S. 7Humalog and 9Trulicity are registered trademarks of Eli Lilly and Company. 11Tanzeum is a registered trademark of GlaxoSmithKline. When using the Savings Card, prices are guaranteed for 12 consecutive monthly fills. For the duration of the program, eligible patients will pay: $99 for a 10mL vial or $149 for a pack of 5 pens per product Maximum quantity of one 10mL vial per fill or one pack of 5 pens per product Offer valid for one fill per product per month Sanofi US reserves the right to rescind, revoke or amend this offer without notice. This site is intended for Continue reading >>

Get To Know The Lantus® Solostar® Pen

Get To Know The Lantus® Solostar® Pen

Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®. Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles. Before starting Lantus®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed. Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus®. Your treatment with TZDs and Lantus® may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including: Sudden weight gain Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements. Lantus® should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus® must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection. While using Lantus®, do not drive or operate heavy machinery until Continue reading >>

Clikstar A New Reusable Insulin Pen For Use With Lantus And Apidra Approved In Eu And Canada

Clikstar A New Reusable Insulin Pen For Use With Lantus And Apidra Approved In Eu And Canada

ClikSTAR A New Reusable Insulin Pen for Use with Lantus and Apidra Approved in EU and Canada Europe, Medtech, Protein Therapeutic, Full Approval, Launches, Endocrine Lantus ClikSTAR and Apidra ClikSTAR Launches Scheduled to Begin in October 2009 Paris, France -- September 30, 2009 -- Sanofi -aventis (EURONEXT: SAN and NYSE: SNY) announced today that ClikSTAR, a new reusable insulin pen, for administration of the 24-hour insulin analog Lantus (insulin glargine [rDNA] injection) or/and the rapid acting insulin analog Apidra(insulin glulisine [rDNA origin] injection), will be available in Europe and Canada in October 2009. ClikSTAR recently received regulatory approval in EU and Canada. ClikSTAR was designed to provide the state-of-the-art performances of the SoloSTAR pen, in a reusable form. Easy-to-use pens such as ClikSTAR bring high degree of flexibility and comfort to patients and may offer an opportunity for earlier initiation of insulin therapy. This may contribute to better glycaemic control, said Professor Alfred Penfornis, Head of the Endocrinology and Diabetology Service, Besanon, France. ClikSTAR is the result of over four years of intensive development and testing of pens, designed in close collaboration with patients and conceived to fulfill patients needs, explained Jean-Philippe Santoni, Senior Vice President, Industrial Development and Innovation, sanofi -aventis. The ClikSTAR delivery system is precise, easy to use and reliable, addressing both patients'expectations and medical needs. Sanofi -aventis, the developer, manufacturer and marketer of ClikSTAR, is currently building a significant manufacturing capability to support the worldwide launch. ClikSTAR will be launched in Canada, Greece, the Netherlands, and Switzerland, in October 2009. With the intr Continue reading >>

What Is The Most Important Information I Should Know About Insulin Glargine (lantus, Lantus Opticlik Cartridge, Lantus Solostar Pen)?

What Is The Most Important Information I Should Know About Insulin Glargine (lantus, Lantus Opticlik Cartridge, Lantus Solostar Pen)?

A A A Medications and Drugs Brand Names: Lantus, Lantus OptiClik Cartridge, Lantus Solostar Pen Generic Name: insulin glargine (Pronunciation: IN su lin AS part, IN su lin AS part PRO ta meen) What is the most important information I should know about insulin glargine (Lantus, Lantus OptiClik Cartridge, Lantus Solostar Pen)? What should I discuss with my healthcare provider before using insulin glargine (Lantus, Lantus OptiClik Cartridge, Lantus Solostar Pen)? What is insulin glargine (Lantus, Lantus OptiClik Cartridge, Lantus Solostar Pen)? Insulin glargine is a man-made form of a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. Insulin glargine is a long-acting form of insulin that is slightly different from other forms of insulin that are not man-made. Insulin glargine is used to treat type 1 or type 2 diabetes. Insulin glargine may also be used for purposes not listed in this medication guide. What are the possible side effects of insulin glargine (Lantus, Lantus OptiClik Cartridge, Lantus Solostar Pen)? Get emergency medical help if you have any of these signs of insulin allergy: itching skin rash over the entire body, wheezing, trouble breathing, fast heart rate, sweating, or feeling like you might pass out. Hypoglycemia, or low blood sugar, is the most common side effect of insulin glargine. Symptoms include headache, hunger, weakness, sweating, tremors, irritability, trouble concentrating, rapid breathing, fast heartbeat, fainting, or seizure (severe hypoglycemia can be fatal). Carry hard candy or glucose tablets with you in case you have low blood sugar. Tell your doctor if you have itching, swelling, redness, or thickening of the skin where you inject insulin glargine. This is not a complete list of side effect Continue reading >>

(insulin Glargine Injection) 100 Units/ml?

(insulin Glargine Injection) 100 Units/ml?

Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Do not use Lantus® to treat diabetic ketoacidosis. Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®. Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles. Before starting Lantus®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed. Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus®. Your treatment with TZDs and Lantus® may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including: Sudden weight gain Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements. Lantus® should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar Continue reading >>

(insulin Glargine Injection) 100 Units/ml

(insulin Glargine Injection) 100 Units/ml

Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®. Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles. Before starting Lantus®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed. Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus®. Your treatment with TZDs and Lantus® may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including: Sudden weight gain Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements. Lantus® should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision. Do NOT dilute or mix Lantus® with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus® must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection. While using Lantus®, do not drive or operate heavy machinery until Continue reading >>

Sanofi's Solostar Hits Us Market Despite Patent Suit

Sanofi's Solostar Hits Us Market Despite Patent Suit

The disposable pen was rolled out in France and Germany earlier this year, but a cloud formed over the company's US plans for the product when reports emerged that Danish firm Novo had filed a patent infringement suit against the company to prevent the pen's availability on the US market. On July 10 Novo filed a suit with the US District Court of New Jersey against Sanofi with regard to the Lantus SoloStar product, but Sanofi has yet to be officially served with the complaint, and says it's understanding of the allegations is still preliminary. Novo's allegations pertain to the mechanisms for injection and dose-setting, features which Sanofi emphasises as advantages of its product but which Novo claims infringe on its NovoPen 4 insulin delivery system. Sanofi states that the dose-setting mechanism on the Lantus SoloStar is somewhat unique, in that it is the only pre-filled disposable insulin pen that allows patients to administer from one up to 80 units in single-unit increments with a single injection. The pen offers a 25 per cent higher capacity than other insulin pens, according to the company, capable of holding 300 units of insulin. The average Lantus dose is 35 units a day. Sanofi also highlights the reduced injection force used with its SoloStar product, with the pressure required to administer the insulin 31 per cent less than Novo's FlexPen device and 54 per cent less than Eli Lilly's Humulin/Humalog pen. A further advantage of the Lantus version of the pen product is that Lantus is currently the only 24-hour insulin approved exclusively for once-daily treatment of hyperglycaemia in patients with Type I or Type II diabetes. It also eliminates the problem of the 'peak-of-action' effect common with other insulins, where the insulin reaches a point of maximum effe Continue reading >>

Lantus Solostar

Lantus Solostar

Generic Name: Insulin Glargine (U-300) Pens (IN su lin GLAR jeen) Brand Name: Lantus Solostar, Toujeo SoloStar Uses of Lantus Solostar: It is used to lower blood sugar in patients with high blood sugar (diabetes). What do I need to tell my doctor BEFORE I take Lantus Solostar? If you have an allergy to insulin or any other part of Lantus Solostar (insulin glargine (U-300) pens). If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. If you have any of these health problems: Acidic blood problem or low blood sugar. This is not a list of all drugs or health problems that interact with this medicine. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Lantus Solostar with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take Lantus Solostar? Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists. Allergic reactions have happened with Lantus Solostar. Rarely, some reactions can be very bad or life-threatening. Talk with the doctor. Low blood sugar may happen with this medicine. Very low blood sugar can lead to seizures, passing out, long lasting brain damage, and sometimes death. Talk with the doctor. Low blood potassium may happen with Lantus Solostar. If not treated, this can lead to a heartbeat that is not normal, very b Continue reading >>

Why Has Lantus Changed From Cartridge To Throw Away Pen?

Why Has Lantus Changed From Cartridge To Throw Away Pen?

Diabetes Forum The Global Diabetes Community Find support, ask questions and share your experiences. Join the community Why has Lantus changed from cartridge to throw away pen? I've been using Lantus (once a day) for years and its very easy to store/carry around as its in cartridge format. Last time I went for a repeat prescription the diabetic nurse tells me that they are now ONLY doing pens that you use once and throw away. I'm very aware of the cost that my diabetes has on the Health Service and the only reason I can think as to why Lantus are moving away from cartridges is a bigger profit for their company. There is so much extra waste, much more packaging and I'll probably need to find a bigger fridge. For me I find it really inconvenient, especially for holidays or when staying away from home. I have also heard that this is possibly the future of short term insulin? Your DSN is wrong, basically. Or, I hate to be cynical, but maybe a Lantus sales rep took her out for lunch? As far as I'm aware there's no move towards throw-away pens. If I were you I'd go back with this page printed out: (see Doseage Forms and Strenghts) and ask her where she got her info from when it's clear that the manufacturer is still producing 10ml vials. It's 3ml cartridges (not 10ml vials) that are needed to be reused in pens, but they're still on list that Snodger's link takes you too. I agree, I'd be livid if my long acting insulin (Humalin I) ceased to be available in cartridges, as I always carry a pen with spares of both short acting and long acting insulins, in case I'm delayed home at night. If you go on the Opticlik site though it says.... "Thank you for visiting OptiClik.com. Because the Lantus Cartridge for use with OptiClik is no longer manufactured, this site is no longer active Continue reading >>

How To Use The Lantus® Solostar® Pen

How To Use The Lantus® Solostar® Pen

Please check the leaflet for the insulin for complete instructions on how to store SoloSTAR®. If your SoloSTAR® is in cool storage, take it out 1 to 2 hours before you inject to allow it to warm up. Cold insulin is more painful to inject. Keep SoloSTAR® out of the reach and sight of children. Keep your SoloSTAR® in cool storage (36°F–46°F [2°C–8°C]) until first use. Do not allow it to freeze. Do not put it next to the freezer compartment of your refrigerator, or next to a freezer pack. Once you take your SoloSTAR® out of cool storage, for use or as a spare, you can use it for up to 28 days. During this time it can be safely kept at room temperature up to 86°F (30°C). Do not use it after this time. SoloSTAR® in use must not be stored in a refrigerator. Do not use SoloSTAR® after the expiration date printed on the label of the pen or on the carton. Protect SoloSTAR® from light. Discard your used SoloSTAR® as required by your local authorities. Protect your SoloSTAR® from dust and dirt. You can clean the outside of your SoloSTAR® by wiping it with a damp cloth. Do not soak, wash, or lubricate the pen as this may damage it. Your SoloSTAR® is designed to work accurately and safely. It should be handled with care. Avoid situations where SoloSTAR® might be damaged. If you are concerned that your SoloSTAR® may be damaged, use a new one. Continue reading >>

Lantus

Lantus

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. (lant-us) What is in this leaflet It does not contain all the available information. It does not take the place of talking to your doctor, pharmacist or diabetes educator. All medicines have risks and benefits. Your doctor has weighed the risks of you using Lantus against the benefits they expect it will have for you. If you have any concerns about using this medicine, ask your doctor or pharmacist. What Lantus is used for Lantus is used to reduce high blood sugar (glucose) levels in people with diabetes mellitus. Lantus is a modified insulin that is very similar to human insulin. It is a substitute for the insulin produced by the pancreas. Lantus is a long-acting insulin. Your doctor may tell you to use a rapid-acting human insulin or oral diabetes medication in combination with Lantus. Ask your doctor if you have any questions about why Lantus has been prescribed for you. Before you use Lantus When you must not use Lantus Some of the symptoms of an allergic reaction may include: If you have a lot of hypos discuss appropriate treatment with your doctor. After the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If you use Lantus after the expiry date has passed, it may not work as well. If it has expired or is damaged, return it to your pharmacist for disposal. If the product appears cloudy, discoloured or contains particles, or if the injection pen/cartridge/vial appears damaged. If you are not sure whether you should start using this medicine, talk to your doctor. There is no experience with the use of Lantus in children less than 6 years. Before you start to use Lantus Tell your doctor if you have allergies to any other medicines, foo Continue reading >>

Performance Of A New Reusable Insulin Pen

Performance Of A New Reusable Insulin Pen

Go to: Abstract The aim of this multinational (Canada, France, Germany, United Kingdom, and United States), task and interview-based study was to compare the ease of use and performance of the ClikSTAR® (sanofi-aventis, Paris, France) insulin pen with other commonly used reusable pens based on participant and interviewer assessments. People with diabetes (n = 654) were asked to demonstrate four pens consecutively—ClikSTAR, Lilly Luxura® (Eli Lilly, Indianapolis, IN), and NovoPen® 3 and 4 (Novo Nordisk, Bagsvaerd, Denmark)—according to the respective instruction manuals. The endpoint was assessed by a rating from the participants and the interviewer. While the participants focused on the pen's ease of use, the interviewer considered the participants' difficulty in preparing and delivering a 40-unit dose and their requirement for help. Results Twenty percent of U.S. participants and 24% of participants from the other countries had type 1 diabetes. Approximately 50% of participants in each group had prior insulin pen experience. A higher proportion of participants, including those with dexterity or visual impairments, reported ClikSTAR as easier to use than other pens (P < 0.05). Participants using ClikSTAR did not experience any difficulty in completing the tasks. The proportion of participants not requiring help in completing the tasks with ClikSTAR was rated as numerically higher than, or similar to, that observed with Lilly Luxura or NovoPen 3 or 4 (75%, 74%, 62%, and 65%, respectively). According to participants, ClikSTAR and NovoPen 4 emerged as the most highly rated pens. Conclusions In comparison with other pens, ClikSTAR was significantly easier to use, which, when taken together with overall performance, meets the need of people with diabetes. Go to: Intro Continue reading >>

Correct Use Of A New Reusable Insulin Injection Pen By Patients With Diabetes: A Design Validation Study

Correct Use Of A New Reusable Insulin Injection Pen By Patients With Diabetes: A Design Validation Study

Go to: Abstract Insulin pen devices are currently being used by approximately half of insulin users worldwide. ClikSTAR® (sanofi-aventis) is a novel reusable insulin pen for injecting either long-acting insulin glargine or short-acting insulin glulisine. The objective of this study was to demonstrate that individuals with diabetes could use the ClikSTAR pen correctly. In this open-label, single-center study, people with diabetes delivered three 40 U insulin doses after receiving training from a diabetes specialist (group A, n = 256) or after self-training (group B, n = 47). Administration of a dose of 75–115% of the intended dose was considered successful. Adverse events (AEs) and product technical complaints (PTCs) were recorded. Results In group A (68% females, 93% Hispanic ethnicity, 97% type 2 diabetes mellitus, mean ± standard deviation age 52 ± 11 years, diabetes duration 11 ± 7 years), half of the participants had prior experience in using insulin pen devices. All except one participant (99.6%) in group A successfully delivered three insulin doses. The lower one-tailed 95% confidence limit for the success rate (98.2%) was higher than the predefined target of 90%. Demographic/baseline characteristics were similar in group B, but 70% had not previously used an injection pen. Group B also showed success; 93.6% of participants successfully completed three dose deliveries. No AEs were reported, although one participant (0.4%) in group A reported one PTC during the training period that was due to a blocked needle. Keywords: design validation, reusable insulin pen device, type 2 diabetes mellitus Go to: Introduction Effective management of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) relies on maintaining glycemic control within the normal r Continue reading >>

Sanofi Receives Ce Mark Approval For Juniorstar Half-unit Insulin Reusable Pen

Sanofi Receives Ce Mark Approval For Juniorstar Half-unit Insulin Reusable Pen

Sanofi has received European approval for the half unit reusable insulin pen called JuniorSTAR. The insulin pen is intended for patients with Type-1 diabetes between six and eighteen years old. The JuniorSTAR provides healthcare professionals greater dosing flexibility due to the half unit dosing increments and can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin). The lightweight pen has a large display, can deliver between 1 to 30 units per injection and has a single-step dial back. The pen is sold in three different colors to provide additional flexibility and allow for differentiation of insulin. A survey conducted by Sanofi in Europe found that 81 percent of patients/parents and 86 percent of nurses agreed that it was easy to carry the pen daily due to its light weight. In addition, 98 percent of patients/parents and 94 percent of nurses agreed that the large display with legible numbering allowed for easy reading of dosage. Finally, 91 percent of patients/parents and 89 percent of nurses concurred that the device’s single-step dial back made dialing back easy, without any insulin leakage. Sanofi has partnered with Haselmeier GmbH, Stuttgart, Germany, to manufacture the JuniorSTAR insulin pen. Press release Sanofi Announces the CE Mark for JuniorSTAR®, a New Half-Unit Insulin Reusable Pen for People with Type 1 Diabetes… Continue reading >>

New Lantus Clikstar Eco-friendly Insulin Pen Now Available In Canada

New Lantus Clikstar Eco-friendly Insulin Pen Now Available In Canada

New Lantus ClikSTAR eco-friendly insulin pen now available in Canada - Easy-to-use and reliable device helps patients achieve their treatment goals - has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in one of the first countries worldwide to launch this state-of-the-art pen. "With the introduction of Lantus ClikSTAR, we offer a new device for patients with type 1 and type 2 diabetes," said Dr. Laurent-Didier Jacobs, Vice-President, Medical Affairs at sanofi-aventis Inc., explaining that Lantus ClikSTAR ideally complements the previously launched Lantus SoloSTAR and Apidra SoloSTAR pre-filled insulin pens. "The Lantus SoloSTAR and Apidra SoloSTAR ready-to-use insulin pens were launched to respond to the different lifestyle needs of patients by providing them with an easier way to self-administer their insulin injections. For this reason, SoloSTAR will continue to be available for patients who find the process of loading or changing insulin cartridges burdensome and even difficult," he said. The Lantus ClikSTAR pen, designed in partnership with nearly 2,000 patients and 500 nurses, is the result of over four years of intensive development and testing aimed at addressing patients' needs. The reusable pen has all the benefits of the pre-filled Lantus SoloSTAR and Apidra SoloSTAR delivery device, including a low injection force, a dial and dose setting that allows patients to administer doses from one to 80 units in a single injection, numbering that is both large and clear that lessens the possibility of injec Continue reading >>

More in insulin